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More than half a century ago, reversible protein phosphor-
ylation was linked to mitochondrial metabolism through the
regulation of pyruvate dehydrogenase. Since this discovery, the
number of identified mitochondrial protein phosphorylation
sites has increased by orders of magnitude, driven largely by
technological advances in mass spectrometry-based phospho-
proteomics. However, the majority of these modifications
remain uncharacterized, rendering their function and rele-
vance unclear. Nonetheless, recent studies have shown that
disruption of resident mitochondrial protein phosphatases
causes substantial metabolic dysfunction across organisms,
suggesting that proper management of mitochondrial phos-
phorylation is vital for organellar and organismal homeostasis.
While these data suggest that phosphorylation within mito-
chondria is of critical importance, significant gaps remain in
our knowledge of how these modifications influence organellar
function. Here, we curate publicly available datasets to map the
extent of protein phosphorylation within mammalian mito-
chondria and to highlight the known functions of
mitochondrial-resident phosphatases. We further propose
models by which phosphorylation may affect mitochondrial
enzyme activities, protein import and processing, and overall
organellar homeostasis.
Phosphorylation and mitochondrial metabolism
Metabolism must respond to dynamic shifts in nutrient
availability and energy demands. Phosphorylation, being a
rapid and reversible posttranslational modification (PTM), is
well suited to calibrate these needs. Indeed, phosphorylation
has long been known to modulate metabolic signaling: the first
protein associated with phosphorylation-based regulation was
glycogen phosphorylase (1)—a discovery first reported in 1955
by Edwin Krebs and Edmond Fischer that earned them the
1992 Nobel Prize in Physiology and Medicine (2).
Early observations also linked phosphorylation to mito-
chondria. Albert Lehninger’s group noted in the mid-1940s that
incorporation of radioactive phosphate into rat liver phospho-
proteins was dependent upon oxidative phosphorylation (3),
and Eugene Kennedy and colleagues first demonstrated cellular
kinase activity against casein using soluble mitochondrial
extract in 1954 (4). However, the discovery of pyruvate dehy-
drogenase (PDH) regulation by phosphorylation in 1969 by
Lester Reed’s group (and Otto Wieland shortly thereafter)
firmly established the role of this PTM inmitochondrial biology
(5, 6).
Since these seminal discoveries, major technological ad-
vances in mass spectrometry (MS)-based quantitative phos-
phoproteomics have uncovered tens of thousands of
phosphorylation sites on proteins across various cell types,
tissues, and organisms (7). By curating many of these datasets,
we found, perhaps surprisingly, that 91% of annotated
mitochondrial proteins have at least one reported phosphor-
ylation site as of March 2021 (Fig. 1A). Furthermore, these
mitochondrial proteins have an average of approximately eight
distinct phosphorylation sites (median = 5, Fig. 1B), demon-
strating that this modification is highly prevalent across the
mitochondrial proteome.
Are these modifications broadly meaningful for mitochon-
drial biology? The answer has remained unclear for some time.
Selecting and biochemically characterizing individual phos-
phorylation events from these large, complex datasets has
proven challenging, obscuring insight into how these modifi-
cations might directly alter mitochondrial protein function.
Thus, despite their prevalence, less than 5% of these phos-
phorylated residues are associated with any published inves-
tigation (Fig. 1C), and even these few “characterized”
modifications often lack critical details regarding function,
stoichiometry (i.e., the fraction of phosphorylated relative to
unphosphorylated protein), and regulation across physiolog-
ical contexts.
By somemeasures, it is reasonable to assume that these PTMs
are a trivial distraction—biological “noise” captured by in-
struments with ever-increasing sensitivity. Indeed, systems-
wide analyses have found that mitochondrial phosphoproteins
typically exhibit low stoichiometry (8). Low-stoichiometry
modifications need not be nonfunctional on principle; modifi-
cations that activate enzyme function, for example, can sub-
stantially alter biological function at low stoichiometry (9). Even
for inhibitory modifications, the collective accumulation of low-
stoichiometry events could decrease organellar function, as has
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been shown for mitochondrial protein acylation modifications
(10, 11). Nonetheless, it is reasonable to assume that low-
stoichiometry modifications are less likely to have biological
impact and may reflect spurious events.
However, other observations suggest that these PTMs may
possess important regulatory value. For example, multiple
studies have found that phosphorylation sites on mitochon-
drial proteins are reproducibly dynamic across physiological
states and models of disease (12–15), implying functionality
(or, at least, nonrandomness). Moreover, the select examples
of purified mitochondrial phosphoproteins or phosphomi-
metics show that these PTMs certainly can alter protein ac-
tivity when present (albeit, often at stoichiometry higher than
what was observed in cells or tissues). Collectively, these ob-
servations demand better answers to two fundamental ques-
tions: are phosphorylation sites on mitochondrial proteins
functionally meaningful? If so, which?
Mitochondria-resident phosphatases
In debating the answers to the questions above, we were
struck by another key data point: mitochondria appear to
possess a set of resident protein phosphatases. The MitoCarta
compendia have included 12 candidate protein phosphatases
(16–18) (Fig. 2A), many of which are conserved across
eukaryotic species, suggesting ancient origins for mitochon-
drial dephosphorylation (19) (Fig. 2B). The presence of 12
mitochondrial phosphatases in a single organelle may, at first
glance, imply substantial functional redundancy, but evidence
suggests that these proteins have distinct, nonoverlapping
roles. First, mitochondrial phosphatases exploit five distinct
catalytic domains, each with specific residue preferences that
confer substrate selectivity (Fig. 2C). Furthermore, these
phosphatases are subcompartmentalized across the organelle
(20–22), physically dividing substrate pools and functions.
RNA-seq profiles of many mitochondrial phosphatases show
tissue-specific expression (23), further diversifying functions
in vivo (Fig. 2D). Finally, genetic or pharmacological pertur-
bation of many mitochondrial phosphatases results in distinct
—and often severe—phenotypes, suggesting that these en-
zymes enable mitochondrial homeostasis through unique
functions.
Given these insights, our approach to addressing the
questions above has been to profile the mitochondrial
phosphoproteome following the perturbation of one of these
phosphatases (24–26). This approach can begin to resolve
two fundamental challenges to understanding the mito-
chondrial phosphorylation network. First, these experiments
identify phosphorylation sites that change in occupancy,
suggesting functional relevance. This is a much needed
prioritization metric for transitioning from high-throughput
datasets to mechanistic investigations. Second, these studies
place mitochondrial phosphatases within a biological
framework, illuminating both the function of the phospha-
tase itself and the pathways dynamically influenced by
phosphorylation. Beyond these biological insights, the study
of phosphatase knockout systems offers a technical strength
in providing a gain-of-signal readout (i.e., elevated phos-
phorylation levels), which can be detected and quantified
more accurately than loss-of-signal approaches. Finally,
recent compendia of mitochondrial proteins include more
candidate protein phosphatases than protein kinases, sug-
gesting that perturbation of these genes provides a more
straightforward strategy for illuminating the mitochondrial
phosphoproteome. This strategy has recently highlighted
surprising and unexpected insights into the influence of
mitochondrial phosphorylation on organellar function and
metabolic homeostasis.
Knockout models of mitochondrial phosphatases
highlight critical organellar functions
Genetic knockout models have been characterized for four
mitochondrial phosphatases in yeast (24, 25, 27), and four in
mice—Pdp1, Ppm1k, Pgam5, and Pptc7. Knockout models of
phosphatases classically associated with metabolism, such as
Pdp1 and Ppm1k, are viable and have phenotypes that likely
derive from their annotated functions, including altered blood
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Figure 1. Phosphorylation is prevalent on mitochondrial proteins. A, of the 1136 proteins identified in MitoCarta 3.0, 1038 have at least one experi-
mentally determined phosphoisoform, while 98 have no reported phosphoisoforms per PhosphoSitePlus as of March 2021 (7). B, histogram analysis
showing the number of phosphoisoforms identified per mitochondrial proteins; the median number of phosphoisoforms is shown with a dotted line. C.
Graphical representation of all experimental identifications of mitochondrial phosphorylation events (8105) versus those with an annotated function (per
the PhosphoSite Plus website). Notably, there is only 4.5% of overlap.
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glucose levels for Pdp1−/− mice and elevated circulating
branched chain amino acids for Ppm1k−/− mice (28, 29).
Knockout of Pgam5 leads to multiple phenotypes, including a
Parkinson’s-like movement disorder and T cell dysfunction
(30, 31). Notably, global phosphoproteomic analysis has not
been performed on these models, suggesting that the full
breadth of substrates and pathways affected by loss of these
phosphatases is not yet known.
We recently generated a global knockout mouse of the
matrix-localized phosphatase Pptc7 (26). Strikingly, the loss of
Pptc7 manifests in severe metabolic abnormalities, including
hypoketotic hypoglycemia, leading to fully penetrant perinatal
lethality within one day of birth. On a cellular level, loss of the
phosphatase markedly diminished mitochondrial content,
suggesting that dephosphorylation of mitochondrial proteins is
somehow critical for maintaining a healthy mitochondrial
population. While the biochemical details of how this occurs
are not fully worked out, these data demonstrate that proper
management of mitochondrial phosphorylation is essential for
mammalian development and, we propose, is of far greater
importance to the biology of this organelle than is currently
appreciated.
The considerable phenotypes exhibited by the four mito-
chondrial phosphatase knockout models demonstrate that at
least a portion of observed mitochondrial phosphorylation
sites hold functional relevance and cannot be attributed to
mere technical artifacts. These observations also add impor-
tant context to the issue of low phosphosite stoichiometry
noted above. First, the reason that mitochondrial phosphosites
exhibit low stoichiometry may be that mitochondrial phos-
phatases constitutively keep them that way. In our study, the
loss of a mitochondrial phosphatase caused elevated stoichi-
ometry at select phosphorylation sites, which subsequently led
to impaired organellar function. This is consistent with the
handful of mitochondrial phosphosites studied in vitro, most
of which were inhibitory to protein function. Second, these
data suggest that performing phosphoproteomic profiling
under physiological conditions whereby the expression of a
select phosphatase is low (e.g., altered nutrient conditions or
elevated stress) could yield very different (i.e., elevated) protein
stoichiometry.
Moving forward, it is essential that we continue to progress
from large-scale profiling to mechanistic investigations of in-
dividual phosphorylation events. It is important to note that in
Figure 2. Mitochondrial phosphatases identified across organisms. A and B, twelve phosphatases localize to mitochondria in mice and humans (A) and
five reside in mitochondria in Sacchraomyces cerevisiae (B). Phosphatases are color-coded according to their phosphatase domain as defined in panel C.
Sublocalization of mitochondrial phosphatases is denoted as follows: matrix localized = circle, inner mitochondrial membrane proteins = triangle, inter-
membrane space proteins = cross, outer membrane proteins = square, and dual-localized proteins, or proteins with unknown localization = star. C, proteins
contain PP2C (red), DUSP (orange), HAD (blue) HP (dark green), and PTP (light green) phosphatase domains in mammalian mitochondria. D, gene expression
data of mitochondrial phosphatases, represented as a heat map of median transcripts per million (TPM) as reported in the GTEx database (23). The heat map
includes all ranges within 100 TPM, except for DUSP26, which has median TPM values of 104 for cerebellum and 193 for skeletal muscle. Gray boxes indicate
transcripts were not quantified.
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mitochondrial phosphatase knockout models, we currently do
not understand whether the observed phenotypes result from
one/a select handful of phosphorylation events, or if the
broader accumulation of phosphorylation on mitochondrial
proteins is somehow collectively detrimental. Relatedly, recent
work has shown that matrix-localized phosphorylation pro-
motes selective mitophagy or turnover of mitochondrial pro-
teins (32), suggesting that the primary effects of
phosphorylation might not lie at the level of individual protein
activity. Further investigations into the mechanisms by which
dysregulated phosphorylation disrupts mitochondrial function
should be an area of active focus in the future.
Where are the kinases?
The severe phenotypes of mismanaged protein phosphory-
lation in knockout models of protein phosphatases naturally
lead to a second question: How do mitochondrial proteins
become phosphorylated? Multiple studies have identified ki-
nases such as PKA that translocate to mitochondria and have
even proposed a complete mitochondria-specific signaling
system comprising G-protein-coupled receptors and cAMP
production (33–36). However, the conditions under which
PKA translocates into mitochondria are not fully worked out,
with some studies suggesting that PKA is not present in the
matrix of select cell types, but instead is only on the outer
mitochondrial membrane bound to an A-kinase anchoring
protein (AKAP) (36). Furthermore, if G-protein-coupled
receptor-mediated PKA activation does occur in the mito-
chondrial matrix, the signals that selectively activate these
intraorganellar pathways, as well as those that resolve such
signals, are not fully understood. Beyond PKA, other pre-
dominantly nonmitochondrial kinases, such as Src family
members, Aurora kinase, and EGFR, have been partially
localized to inner mitochondrial compartments (37–39).
However, similar to PKA, the mechanisms by which they
translocate, the signals prompting this translocation, and the
systems underlying their organellar-specific regulation are not
known.
Alternatively, it is possible that protein kinases long known
to be resident in the mitochondrial matrix, such as the PDH
kinases (PDKs) and the branched chain amino acid dehydro-
genase (BCKDH) kinase (BCKDK), have broader substrate
profiles than currently appreciated. These kinases are classi-
cally thought to have limited protein kinase activity across the
mitochondrion due to their physical association with their
respective dehydrogenase complexes (5, 40, 41). To our
knowledge, this assumption has not been thoroughly tested,
and some observations suggest that the PDKs and BCKDK
may have a more diverse substrate pool than PDH and
BCKDH. First, proximity labeling studies have shown at least
three PDK isoforms with non-PDH interactors (42), chal-
lenging the notion that the PDKs are sequestered to the PDH
complex. Second, treatment of porcine heart mitochondria
with the pan-PDK inhibitor dichloroacetate and pyruvate
diminished 32P-incorporation into multiple unidentified pro-
teins, consistent with a model in which PDK isoforms phos-
phorylate proteins beyond PDH (43). Finally, recent work
identified an unexpected role for BCKDK in the phosphory-
lation and regulation of ACLY—a cytosolic enzyme involved
in fatty acid synthesis (44). Thus, noncanonical roles for
the PDKs and BCKDK—both within and outside of mito-
chondria—seem likely and may influence mitochondrial
phosphorylation profiles more than currently appreciated.
A third possibility invokes the action of resident atypical or
metabolic kinases in phosphorylating mitochondrial proteins.
Mammalian mitochondria contain five atypical “ADCK” ki-
nases, which are members of the protein kinase-like (PKL)
superfamily (45). Early on, one of these proteins (Coq8 in
Saccharomyces cerevisiae) was linked to coenzyme Q biosyn-
thesis and was postulated to directly phosphorylate proteins
within the coenzyme Q pathway (46). However, structural
analysis revealed that ADCK proteins possess multiple features
poised to inhibit protein kinase activity, including an N-ter-
minal domain that occupies the typical substrate-binding
pocket (45, 47). Recent studies suggest that ADCKs more
likely function as ATPases (48), although Coq8 and its
mammalian orthologs are the only ADCKs that have been
tested rigorously in vitro and in vivo. Beyond the ADCKs, 24
other small-molecule kinases reside within mitochondria that
phosphorylate nucleotides (e.g., the adenylate kinases AK2-4),
lipids (e.g., sphingosine kinase, SPHK2), metabolites (e.g.,
phosphoenolcarboxykinase 2, PCK2), or unknown substrate
classes (e.g., ACAD10 and ACAD11). Emerging evidence
suggests that metabolic kinases may moonlight as protein ki-
nases (49), and thus careful biochemical studies are needed to
determine whether these kinases may contribute to mito-
chondrial protein phosphorylation.
A final model posits that resident mitochondrial protein
kinases are not needed at all. In our Pptc7 work, we identi-
fied elevated occupancy on phosphorylation sites at or within
the mitochondrial targeting sequence (MTS) of multiple
precursor proteins (26). The MTS—a short, N-terminal
segment found on many mitochondrial precursors—is
removed upon entry to the organelle and is thus unlikely to
influence mature protein function. Despite this, more than
40% of MTS-containing mitochondrial proteins are phos-
phorylated within or proximal to this sequence (Fig. 3).
These data suggest that phosphorylation may occur by
cytosolic kinases prior to protein import and thus may in-
fluence the mitochondrial import and/or processing of pre-
cursor proteins. If phosphorylated mitochondrial precursors
can be imported into mitochondria (as, it seems, they can in
plastids (50)), this phenomenon might extend to much of the
observed mitochondrial phosphoproteome. This mechanism
would allow cross-compartmental regulation of mitochon-
drial phosphorylation, as cytosolic kinases, activated in
response to various cellular cues, could phosphorylate
mitochondrial precursors to affect their organellar targeting
and function. This could provide a rapid and reversible
mechanism to enrich specific molecular targets within
mitochondria under dynamic cellular conditions. Further-
more, this mechanism could explain two current mysteries in
the field of mitochondrial phosphorylation: (1) the paucity of
mitochondrial-localized kinases relative to mitochondrial
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phosphatases, and (2) at least for MTS phosphorylation, the
low stoichiometry, because they are inherently transient and
resolved after import.
Future directions and conclusions
The past decade has brought forth an incredible surge in the
quality and quantity of phosphoproteomic studies. These
studies, which span cellular and animal models, have revealed
the unexpected prevalence of phosphorylation on mitochon-
drial proteins. However, questions remain regarding which of
these modifications influence organellar function and the
physiological conditions under which proteins become phos-
phorylated within the organelle.
Important next steps in understanding the systems-wide
effects of phosphorylation in mitochondria include profiling
the functions of mitochondrial phosphatases to understand
not only their substrates and molecular functions but also how
these translate into physiological dysfunction across organ-
isms. Of the 12 known mitochondrial phosphatases, six (i.e.,
Cecr5, Dusp18, Dusp21, Dusp26, Cdc25c, and Ptpn4) have no
known substrates within mitochondria. We propose that a
concerted effort to profile phosphatase knockout models with
quantitative phosphoproteomic and metabolomic techniques
will be key to establishing clear phosphatase–substrate re-
lationships and for prioritizing biologically relevant modifica-
tions that affect mitochondrial processes. Furthermore,
understanding the contexts under which mitochondrial
phosphatases are regulated will elucidate a broader mito-
chondrial signaling network and help clarify how dynamic
phosphorylation coordinates organellar function.
Finally, understanding mitochondrial phosphorylation may
lead to new therapeutic options for elevating mitochondrial
metabolism. Recent studies have already shown that kinase
inhibition can alleviate mitochondrial dysfunction in mouse
models of mitochondrial disease by dampening mTOR, PKC,
or AMPK signaling (51–53). While it remains unclear how and
to what extent the mitochondrial phosphoproteome is affected
in each of these studies, these data collectively suggest that
protein phosphorylation critically regulates mitochondrial
function and may have therapeutic implications if properly
exploited.
Mounting data suggest that reversible phosphorylation may
be a widespread and underappreciated means of regulation
within mitochondria and that its mismanagement could be an
important underlying feature of mitochondrial pathophysi-
ology. Rigorous new efforts to understand which mitochon-
drial proteins are affected by phosphorylation, to establish
mechanistically how it alters their function, and to identify the
enzymes that manage these modifications could motivate a
powerful new therapeutic strategy: the control of mitochon-
drial metabolism via manipulation of intraorganellar phos-
phorylation networks.
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Figure 3. Numerous mitochondrial proteins are phosphorylated near their N-termini. A, N-terminal cleavage sites that likely reflect a mitochondrial
targeting sequence (MTS) were determined for 437 proteins. Of these, 193, or 44.2%, are phosphorylated within or proximal to their N-terminal cleaved
region. B, distribution of lengths of cleaved N-termini of 437 proteins, binned by ten amino acid groups (e.g., 1–10 amino acids). Gray bars reflect distribution
of all 437 proteins by cleaved N-terminal length, blue bars reflect distribution of proteins phosphorylated within their cleaved N-terminus.
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